Tiziana Life Sciences Ltd (TLSA)

Market Cap	192.71M +143.7%
Revenue (ttm)	n/a
Net Income	-12.84M
EPS	-0.11
Shares Out	127.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	282,000
Open	1.590
Previous Close	1.600
Day's Range	1.460 - 1.600
52-Week Range	0.630 - 2.600
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	May 6, 2025

About TLSA

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for u...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 24, 2000
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: TLSA
• Website: https://www.tizianalifesciences.com